Impact of patient ethnicity on the metabolic and immunologic effects of PI3K–mTOR pathway inhibition in patients with solid tumor malignancies

Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma

(2013) Ki Hyang Kim et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2

(2013) Shinzaburo Noguchi et al.   Breast Cancer

Management of Treatment-Related Toxicity with Targeted Therapies for Renal Cell Carcinoma: Evidence-Based Practice and Best Practices

(2011) Laurie Appleby et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Differential Expression of MicroRNAs in CD34+ Cells of 5q- Syndrome

(2011) Hana Votavova et al.   Journal of Hematology & Oncology

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

mTOR couples cellular nutrient sensing to organismal metabolic homeostasis

(2011) Jessica J. Howell et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Mechanism and Management of AKT Inhibitor-Induced Hyperglycemia

(2008) M.-C. Crouthamel et al.   CLINICAL CANCER RESEARCH

mTOR Inhibition by Rapamycin Prevents  -Cell Adaptation to Hyperglycemia and Exacerbates the Metabolic State in Type 2 Diabetes

(2008) M. Fraenkel et al.   DIABETES

Potential Regional Differences for the Tolerability Profiles of Fluoropyrimidines

(2008) Daniel G. Haller et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET